{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:33:25Z","timestamp":1789216405294,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Israel Institute for Biological Research","award":["SB\/5122-18"],"award-info":[{"award-number":["SB\/5122-18"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Protein Expression and Purification"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.pep.2015.02.008","type":"journal-article","created":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T02:15:22Z","timestamp":1424916922000},"page":"122-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Expression, purification and characterization of the receptor-binding domain of botulinum neurotoxin serotype B as a vaccine candidate"],"prefix":"10.1016","volume":"110","author":[{"given":"Alon","family":"Ben David","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amram","family":"Torgeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Barnea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Zichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pep.2015.02.008_b0005","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0733-8627(02)00005-6","article-title":"Threats in bioterrorism I: CDC category a agents","volume":"20","author":"Darling","year":"2002","journal-title":"Emerg. Med. Clin. North Am."},{"key":"10.1016\/j.pep.2015.02.008_b0010","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1615\/CritRevImmunol.v27.i4.20","article-title":"Botulinum neurotoxin vaccines: past, present, and future","volume":"27","author":"Smith","year":"2007","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.pep.2015.02.008_b0015","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4161\/hv.9420","article-title":"Botulinum neurotoxin vaccines: past history and recent developments","volume":"5","author":"Rusnak","year":"2009","journal-title":"Hum. Vaccin."},{"key":"10.1016\/j.pep.2015.02.008_b0020","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1146\/annurev.biochem.051908.125345","article-title":"Botulinum neurotoxin a marvel of protein design","volume":"79","author":"Montal","year":"2010","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.pep.2015.02.008_b0025","doi-asserted-by":"crossref","first-page":"D33","DOI":"10.1016\/j.vaccine.2009.08.059","article-title":"Botulism and vaccines for its prevention","volume":"27","author":"Smith","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.pep.2015.02.008_b0030","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1128\/IAI.63.7.2738-2742.1995","article-title":"Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli","volume":"63","author":"Clayton","year":"1995","journal-title":"Infect. Immun."},{"key":"10.1016\/j.pep.2015.02.008_b0035","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1128\/IAI.01025-07","article-title":"Subunit vaccine against the seven serotypes of botulism","volume":"76","author":"Baldwin","year":"2008","journal-title":"Infect. Immun."},{"key":"10.1016\/j.pep.2015.02.008_b0040","doi-asserted-by":"crossref","first-page":"7313","DOI":"10.1016\/j.vaccine.2010.08.076","article-title":"Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A\/B)","volume":"28","author":"Shearer","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.pep.2015.02.008_b0045","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/0041-0101(95)00072-T","article-title":"Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen","volume":"33","author":"LaPenotiere","year":"1995","journal-title":"Toxicon"},{"key":"10.1016\/j.pep.2015.02.008_b0050","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.toxicon.2006.02.013","article-title":"Recombinant C fragment of botulinum neurotoxin B serotype (rBoNTB (HC)) immune response and protection in the rhesus monkey","volume":"47","author":"Boles","year":"2006","journal-title":"Toxicon"},{"key":"10.1016\/j.pep.2015.02.008_b0055","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1128\/IAI.66.10.4817-4822.1998","article-title":"Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate","volume":"66","author":"Byrne","year":"1998","journal-title":"Infect. Immun."},{"key":"10.1016\/j.pep.2015.02.008_b0060","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1006\/prep.2000.1200","article-title":"Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris","volume":"18","author":"Byrne","year":"2000","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.pep.2015.02.008_b0065","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.pep.2005.08.015","article-title":"Purification and scale-up of a recombinant heavy chain fragment C of botulinum neurotoxin serotype E in Pichia pastoris GS115","volume":"45","author":"Dux","year":"2006","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.pep.2015.02.008_b0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pep.2010.09.016","article-title":"Purification of a recombinant heavy chain fragment C vaccine candidate against botulinum serotype C neurotoxin [rBoNTC(Hc)] expressed in Pichia pastoris","volume":"75","author":"Dux","year":"2011","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.pep.2015.02.008_b0075","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1006\/prep.2000.1256","article-title":"Production and purification of the heavy chain fragment C of botulinum neurotoxin, serotype A, expressed in the methylotrophic yeast Pichia pastoris","volume":"19","author":"Potter","year":"2000","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.pep.2015.02.008_b0080","doi-asserted-by":"crossref","first-page":"6998","DOI":"10.1128\/IAI.73.10.6998-7005.2005","article-title":"Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E","volume":"73","author":"Baldwin","year":"2005","journal-title":"Infect. Immun."},{"key":"10.1016\/j.pep.2015.02.008_b0085","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.clim.2010.07.005","article-title":"Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F","volume":"137","author":"Yu","year":"2010","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.pep.2015.02.008_b0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pep.2009.11.007","article-title":"Improved soluble expression and characterization of the Hc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli by using a PCR-synthesized gene and a Trx co-expression strain","volume":"71","author":"Chen","year":"2010","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.pep.2015.02.008_b0095","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S1872-2075(07)60052-1","article-title":"High-level expression of the Hc domain of clostridium botulinum neurotoxin serotype A in Escherichia coli and its immunogenicity as an antigen","volume":"23","author":"Yu","year":"2007","journal-title":"Chin. J. Biotechnol."},{"key":"10.1016\/j.pep.2015.02.008_b0205","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1128\/CVI.00268-13","article-title":"The receptor binding domain of botulinum neurotoxin serotype A (BoNT\/A) inhibits BoNT\/A and BoNT\/E intoxications in vivo","volume":"20","author":"Ben David","year":"2013","journal-title":"Clin. Vacc. Immun."},{"key":"10.1016\/j.pep.2015.02.008_b0105","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1128\/CVI.00493-09","article-title":"Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B","volume":"17","author":"Held","year":"2010","journal-title":"Clin. Vacc. Immun."},{"key":"10.1016\/j.pep.2015.02.008_b0110","doi-asserted-by":"crossref","first-page":"462","DOI":"10.4161\/hv.6.6.11709","article-title":"Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen","volume":"6","author":"Gao","year":"2010","journal-title":"Hum. Vaccin."},{"key":"10.1016\/j.pep.2015.02.008_b0115","doi-asserted-by":"crossref","first-page":"e87089","DOI":"10.1371\/journal.pone.0087089","article-title":"Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations","volume":"9","author":"Diamant","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pep.2015.02.008_b0120","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1128\/CVI.00496-09","article-title":"Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system","volume":"17","author":"Zichel","year":"2010","journal-title":"Clin. Vacc. Immun."},{"key":"10.1016\/j.pep.2015.02.008_b0125","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1128\/AEM.58.8.2345-2354.1992","article-title":"Molecular cloning of the Clostridium botulinum structural gene encoding the type B neurotoxin and determination of its entire nucleotide sequence","volume":"58","author":"Whelan","year":"1992","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.pep.2015.02.008_b0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0168-1656(94)00143-Z","article-title":"Simple fed-batch technique for high cell density cultivation of Escherichia coli","volume":"39","author":"Korz","year":"1995","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.pep.2015.02.008_b0135","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1093\/nar\/gkg563","article-title":"ExPASy: the proteomics server for in-depth protein knowledge and analysis","volume":"31","author":"Gasteiger","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.pep.2015.02.008_b0140","unstructured":"European Pharmacopoeia, Botulinum antitoxin, 2011."},{"key":"10.1016\/j.pep.2015.02.008_b0145","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.febslet.2004.07.001","article-title":"Identification of the catalytic residues in the double-zinc aminopeptidase from Streptomyces griseus","volume":"571","author":"Fundoiano-Hershcovitz","year":"2004","journal-title":"FEBS Lett."},{"key":"10.1016\/j.pep.2015.02.008_b0150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pep.2006.06.025","article-title":"Improved conditions for production of recombinant plant sequitepene synthase in Escherichia coli","volume":"51","author":"Picaud","year":"2007","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.pep.2015.02.008_b0155","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.pep.2006.09.015","article-title":"Effect of osmotic stress and heat shock in recombinant protein overexpression and crystallization","volume":"52","author":"Oganeysyan","year":"2007","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.pep.2015.02.008_b0160","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1016\/j.vaccine.2005.11.028","article-title":"Phase I safety and immunogenecity trial of FMP1\/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine","volume":"24","author":"Ockenhouse","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.pep.2015.02.008_b0165","doi-asserted-by":"crossref","first-page":"e1465","DOI":"10.1371\/journal.pone.0001465","article-title":"Safety and immunogenecity of an AMA-1 malaria vaccine in malian adults: results of a phase 1 randomized control trial","volume":"3","author":"Thera","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.pep.2015.02.008_b0170","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.bbagen.2006.03.027","article-title":"Structural analysis and classification of native proteins from E. coli commonly co-purified by immobilised metal affinity chromatography","volume":"1760","author":"Bolanos-Garcia","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.pep.2015.02.008_b0175","doi-asserted-by":"crossref","first-page":"23000","DOI":"10.1074\/jbc.M501534200","article-title":"Structure and function of both domains of ArnA, a dual function decarboxylase and a formyltransferase, involved in 4-amino-4-deoxy-l-arabinose biosynthesis","volume":"280","author":"Williams","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pep.2015.02.008_b0180","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1002\/prot.24364","article-title":"Optimized E. coli expression strain LOBSTR eliminates common contaminants from his-tag purification","volume":"81","author":"Andersen","year":"2013","journal-title":"Proteins"},{"key":"10.1016\/j.pep.2015.02.008_b0185","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.str.2005.03.018","article-title":"Structure and mechanism of ArnA: conformational change implies ordered dehydrogenase mechanism for polymyxin resistance","volume":"13","author":"Gatzeva-Topalova","year":"2005","journal-title":"Structure"},{"key":"10.1016\/j.pep.2015.02.008_b0190","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1128\/AEM.00119-11","article-title":"Engineering Escherichia coli BL21(DE3) derivatives strains to minimize E. coli protein contamination after purification by immobilized metal affinity chromatography","volume":"77","author":"Robichon","year":"2011","journal-title":"Appl. Environ. Microbiol."},{"key":"10.1016\/j.pep.2015.02.008_b0195","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1006\/prep.1998.0910","article-title":"Production and purification of the heavy-chain fragment C of botulinum neurotoxin, serotype B, expressed in the methylotrophic yeast Pichia pastoris","volume":"13","author":"Potter","year":"1998","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.pep.2015.02.008_b0200","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1083\/jcb.200305098","article-title":"Synaptotagmins I and II mediate entry of botulinum neurotoxins B into cells","volume":"162","author":"Dong","year":"2003","journal-title":"J. Cell Biol."}],"container-title":["Protein Expression and Purification"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046592815000200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1046592815000200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T05:16:02Z","timestamp":1598764562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1046592815000200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":40,"alternative-id":["S1046592815000200"],"URL":"https:\/\/doi.org\/10.1016\/j.pep.2015.02.008","relation":{},"ISSN":["1046-5928"],"issn-type":[{"value":"1046-5928","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression, purification and characterization of the receptor-binding domain of botulinum neurotoxin serotype B as a vaccine candidate","name":"articletitle","label":"Article Title"},{"value":"Protein Expression and Purification","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pep.2015.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}